Management of post-autologous transplant relapse in patients with T-cell lymphomas.
Am J Hematol
; 99(8): 1485-1491, 2024 08.
Article
in En
| MEDLINE
| ID: mdl-38661220
ABSTRACT
Autologous hematopoietic cell transplantation (AHCT) is often used as a consolidation for patients with peripheral T-cell lymphomas (PTCLs) due to the poor prognosis associated with this heterogenous group of disorders. However, a significant number of patients will experience post-AHCT disease relapse. Here, we report a retrospective study of consecutive 124 patients with PTCLs who underwent AHCT from 2008 to 2020. With a median follow-up of 6.01 years following AHCT, 49 patients (40%) experienced disease relapse. As expected, more patients who were not in first complete remission experienced post-AHCT relapse. Following relapse, majority of the patients (70%) receiving systemic therapies intended as bridging to curative allogeneic HCT. However, only 18 (53%) patients eventually underwent allogeneic HCT. The estimated 3-year OS among patients proceeding to allogeneic HCT was 72% (95% CI 46%-87%). Our report details the pattern of post-AHCT relapse and the management of relapsed disease using different therapeutic modalities.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, T-Cell, Peripheral
/
Hematopoietic Stem Cell Transplantation
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Am J Hematol
Year:
2024
Document type:
Article
Affiliation country: